"HAYLEY'S COMET"

HAYLEY'S COMET

Abrégé anglais

A new cultivar of medicinal cannabis has been bred that renders large amounts
of
cannabidiolic acid (mg/gram ground flower weight)... greater than 10%. The
cultivar
moved from an outdoor to indoor environment produced similar levels of
cannabidiolic
(CBD) and similar cannabinoid profiles. Reproduced asexually, the same
(greater than
10%) cannabidiolic acid amounts were rendered and this remains constant crop
to crop.
THC levels do not change between 20 and 30% of that of the CBD-A
concentration.
High Pressure Liquid Chromatography (HPLC) determines Cannabinoid profiles
where
the amounts of the three most abundant cannabinoids (tetrahydrocannabinol,
cannabinol
and cannabidiol) and their acids are quantified. The cannabinoid profile
relates directly to
the physiological effects of the plant as a medicine. In addition, a genetic
fingerprint of
the strain has been generated using gel electrophoresis. Strains high in
cannabidiolic acid
are rare since commercial breeding has led to strains with large
concentrations of
tetrahydrocannabinol (THC) and very little cannabidiol making the strain in
question
rare. Hayley's Comet provides a unique cannabinoid profile containing large
concentrations of CBD-A making it useful for medicaments for seizure disorder,
pain and
inflammation.

Revendications

Claims:
Claim 1: A method whereby a unique cannabinoid profile as determined by High
Pressure Liquid Chromatography (HPLC), defines a specific cultivar of
asexually
reproducing cannabis.
Claim 2: A method whereby a genetic profile (fingerprint), defines a specific
cultivar of
asexually reproducing cannabis.
Claim 3: A method whereby a cannabidiolic acid concentration of greater than
100
mg/gram (of ground flower weight), is consistently found in the specific
cultivar of
Claim 4: A method whereby a tetrahydrocannabinol concentration of less than
15% (of
ground flower weight), is consistently found in the specific cultivar of
asexually
reproducing cannabis.
Claim 5: A method whereby the DNA profile at locus Cind 16FR (bp) differs from
other
comparable strains and having a distinct fragment pattern characteristic of
the cultivar.
Claim 6: A method whereby the DNA profile at locus Cind1FR differs from other
comparable strains and having a distinct fragment pattern characteristic of
the cultivar.
Claim 7: A method whereby the DNA profile at locus Cind5 differs from other
comparable strains and having a distinct fragment pattern characteristic of
the cultivar.
Claim 8: A method whereby the DNA profile at locus Cind24FR differs from other
comparable strains and having a distinct fragment pattern characteristic of
the cultivar.

Description

CA 02737447 2011-04-29
Table 1: Genetic Profile of Hayley's comet
Cind 16FR (bp) Cind1FR Cind5 Cind24FR
Ha le 's comet 84 88 90 104 108 214 224 215 324 144 167
Cindl 96 102 108 214 214 173 226 221 221
Blueberry 88 90 102 108 212 212 220 320 193 193
U pick 88 90 108 110 226 226 200 320 187 187
Table 1: demonstrates the 4-locus DNA profile (Cind1FR, Cind5FR, Cindl6FR, and
Cind24FR) for Hayley's comet. Across the table the differences in fragment
size for the 4
plants compared (HC, Cindl, Blueberry and Upick). Each number corresponds to
an
'allele' located in the cannabis genome. One locus is complex (Cind16FR) and
gives rise
to more than two alleles (3-5) while the other three loci (1,5,and 24) are
typical diploids,
either homozygous where allele sizes are the same, or heterozygous where the
two allele
are different.
Claim 9: The cultivar (Hayley's Comet), described here provides a cannabinoid
profile
useful in the treatment of epilepsy.

CA 02737447 2011-04-29
Background of the Invention:
Patent No. 2694325 speaks to synthetic analogues of Cannabidiol; the invention
described here refers to natural cannabidiolic acid compounds and their
decarboxylated
derivatives.
Patent No. 2499210 speaks to cannabidiol in a highly pure form, greater than
95%, that
can be used in medical studies, whereas the invention described here is a
means of
obtaining cannabidiolic acid in its natural form, plus inclusion of the other
natural
cannabinoids.
Patent No. 2411831 speaks to uses of cannabidiol in pure form; the invention
described
here addresses cannabidiolic acid in its natural form and means of obtaining
it.
Patent No. 2424356 speaks to extraction of tetrahydrocannabinol and
cannabidiol using
super critical fluid extraction whereas the invention described here employs
no extraction
of the compounds from the plant.
Patent No. 2692539 speaks to ratios of cannabidiol to cannabivarin as
antagonists to the
CB 1 and CB2 receptors, whereas the invention described here is merely a
continued
source of cannabidiolic acid and other carboxylated cannabinoids.
A strain with high concentrations of cannabidiolic acid was bred, whereby with
asexual
reproduction cannabidiolic acid concentrations (as determined by HPLC) remain
consistent and the genetic fingerprint remains inimitable within cannabis sub-
species.
The DNA profile was generated using (methodology) and compared to a number of
common strains of similar type. The unique DNA finger-print plus the
cannabinoid
profile characterize the strain, plus morphological description, cloning,
growth and pest
resistance add to distinguishing this plant from others of its type.
Objectives of the Invention:
1.) An objective of the invention is to preserve a strain of cannabis with
unique
cannabinoid and DNA profiles, represented by high cannabidiolic acid to
tetrahydrocannabinolic acid ratios.
2.) A further objective of the invention is to preserve a strain of cannabis
with high ratios
CBD-A to THC-A to be used in medicaments.

CA 02737447 2011-04-29
4
3.) A further objective of the invention is to propagate the strain for yields
of CBD-A.
4.) A further objective of the invention is to propagate the strain for use in
medicaments
for chronic pain and seizure disorder.
5.) A further objective of the invention is to propagate a strain with
consistent
cannabinoid profiles of high CBD-A to THC-A ratios.
6.) A further objective of the invention is to use this strain to breed other
strains with a
high CBD-A to THC-A ratio.
Summary of the Invention:
A single cultivar of cannabis has been bred with distinct HPLC and DNA
profiles.
The cultivar is asexually reproduced with cloning such that a cannabinoid
profile
with greater than 100 mg/gram (of ground flower weight) CBD-A is consistently
produced and the THC concentration consistently less than 150 mg/gram, of
ground
flower weight.

Dessin représentatif